Introduction {#section1-1179547618765761}
============

A search of the current literature was performed using the PubMed database which let us to take 168 articles, analyzing them and adding others from bibliography database, we obtained 236 cases of pancreatitis in peritoneal dialysis (PD) (17 case reports,^[@bibr1-1179547618765761][@bibr2-1179547618765761][@bibr3-1179547618765761][@bibr4-1179547618765761][@bibr5-1179547618765761][@bibr6-1179547618765761][@bibr7-1179547618765761][@bibr8-1179547618765761][@bibr9-1179547618765761][@bibr10-1179547618765761][@bibr11-1179547618765761][@bibr12-1179547618765761][@bibr13-1179547618765761][@bibr14-1179547618765761][@bibr15-1179547618765761][@bibr16-1179547618765761]--[@bibr17-1179547618765761]^ 5 case series,^[@bibr18-1179547618765761][@bibr19-1179547618765761][@bibr20-1179547618765761][@bibr21-1179547618765761]--[@bibr22-1179547618765761]^ 11 population-based studies^[@bibr23-1179547618765761][@bibr24-1179547618765761][@bibr25-1179547618765761][@bibr26-1179547618765761][@bibr27-1179547618765761][@bibr28-1179547618765761][@bibr29-1179547618765761][@bibr30-1179547618765761][@bibr31-1179547618765761][@bibr32-1179547618765761]--[@bibr33-1179547618765761]^).

In 15 articles it was documented the concomitance of peritonitis, from databases with reached that only 25 from 44 patients had concomitance peritonitis in PD.

Fungal infection is common in patients on PD. Peritonitis is an important complication of the PD; only in some cases the fungal peritonitis is recognized but with 15%-45% of mortality rate.^[@bibr34-1179547618765761]^

The clinical features of pancreatitis in patients with chronic kidney disease are no different from those in the general population. The only exception is the coexistence of peritonitis and pancreatitis which is clinically difficult to differentiate.^[@bibr25-1179547618765761]^

The incidence of acute and chronic pancreatitis is increased in PD for the high level of uremic toxin, local hypercalcemia, and toxicity of peritoneal dialysate.^[@bibr2-1179547618765761],[@bibr3-1179547618765761]^ In these patients, the diagnosis is based on the clinical and radiological evaluations because of the altered level of pancreatic enzyme in PD. More often, acute pancreatitis is associated with complete healing without complications, but can complicate to pseudocyst formation in some other cases, which in some condition may require drainage intervention. Until now, there is no specific treatment guideline for pancreatitis in PD, so we handled our case initially with empiric therapy and ensuing according to the dialysis liquid and blood culture results. The peculiarity of this case is represented by numerous morbidities that the patient developed simultaneously, with the genesis of a complex clinical picture, by the combination of infections due to *Candida albicans* and *Acinetobacter baumannii*.

Case Report {#section2-1179547618765761}
===========

A 54-year-old woman was hospitalized for abdominal pain, nausea, vomiting, anorexia, and fever, in poor clinical condition, with fever, and unstable hemodynamic state.

Past medical history of the patient is as follows:

-   Hepatitis C virus positive;

-   Chronic glomerulonephritis caused by glomerulonephritis of unknown cause in 2002, on hemodialysis from 2007 to 2012, failure of first renal transplantation in 2008 for acute rejection, failure of second transplantation from living donor in 2012 for acute rejection, successive start of hemodialysis, and interrupted after 1 year for vascular access problems. On February 2013, peritoneal dialysis catheter was placed.

-   Secondary hyperparathyroidism;

-   Steno-obstructive vasculopathy, percutaneous transluminal angioplasty in subclavian vein on January 2013;

-   Hypertension;

-   Recently, she was hospitalized for acute pancreatitis, treated with antibiotics, and consequently temporarily changed from peritoneal dialysis to hemodialysis (2 weeks).

Abdominal physical examination demonstrated epigastric and left lower quadrant tenderness. Blood examination showed leukocytosis with neutrophil left shift and increased levels of inflammatory markers.

Few hours after recovery, the patient underwent PD exchange; the liquid in the dialysis bag appeared yellow and cloudy. On the basis of the white blood cell count and peritoneal culture examination, we added tobramycin and vancomycin to peritoneal dialysate.

After 2 days from recovery, the peritoneal fluid culture was positive for *C albicans* peritonitis.

Therefore, the peritoneal catheter was removed, a right femoral central venous catheter (CVC) line was inserted, meropenem and anidulafungin were started, and tacrolimus was interrupted.

Contrast enhanced computed tomography (CT) scan of the abdomen and abdominal magnetic resonance imaging (MRI) without contrast evidence "numerous pseudo cystic formation containing the corpuscular liquid defined by a thick wall adherent to the corpo caudal of the pancreas, long to the anterior zone of the left renal, that extends from the retro cavity of the greater omentum in the anterior para renal to the left lateral conal interfacial" ([Figure 1](#fig1-1179547618765761){ref-type="fig"}, panel A). Consequently, an acute complicated pancreatitis with pseudocyst was diagnosed.

![Panel A: pancreatic pseudocyst in abdominal computed tomographic scan. Panel B: abdominal magnetic resonance imaging, percutaneous cystogastrostomy drainage.](10.1177_1179547618765761-fig1){#fig1-1179547618765761}

A CT-guided percutaneous cystogastrostomy catheter was maintained to drain purulent fluid ([Figure 1](#fig1-1179547618765761){ref-type="fig"}, panel B) for 25 days.

After 2 weeks from the recovery, for the dyspnea and hypoxia, due to pulmonary consolidation and severe bilateral pleural effusion, 3 times of plural effusion tapping was needed.

After 1 month of recovery, for the febrile peaks after the dialysis session, the CVC culture examination and hemoculture were positive to *Acinetobacter* so the patient at first developed candida peritonitis and then sepsis due to *A baumannii*. The blood examination revealed procalcitonin \>200 ng/mL and β-[d]{.smallcaps}-glucan \>523 pg/mL. The therapy was modified as reported in [Table 1](#table1-1179547618765761){ref-type="table"}. Despite the sepsis state was due to the femoral CVC infection, for the steno-obstructive pathology, it was not possible remove the femoral catheter.

###### 

Therapeutic regimen.

![](10.1177_1179547618765761-table1)

  Date       Antimicrobial therapy
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1st day    Fluconazole 400 mg daily intravenously + meropenem 1 g twice a day
  2nd day    Fluconazole 200 mg daily intravenously + meropenem 1 g daily intravenously
  3rd day    Fluconazole 200 mg daily intravenously + meropenem 1 g daily intravenously + ciprofloxacin 200 mg daily intravenously
  4th day    Fluconazole 200 mg daily intravenously + meropenem 1 g daily intravenously + ciprofloxacin 200 mg daily intravenously + anidulafungin 100 mg daily intravenously
  14th day   Tigecycline 50 mg twice a day intravenously + piperacillin/tazobactam 2.5 mg 3 times a day + anidulafungin 100 mg daily intravenously
  19th day   Tigecycline 50 mg twice a day intravenously+ anidulafungin 100 mg daily intravenously + linezolid 2 mg/mL intravenously
  24th day   Meropenem 500 mg daily intravenously in HD days and meropenem 500 mg twice a day intravenously in non-HD days + anidulafungin 100 mg daily intravenously + linezolid 2 mg/mL intravenously
  30th day   Meropenem 500 mg daily intravenously in HD days and meropenem 500 mg twice a day intravenously in non-HD days + anidulafungin 100 mg daily intravenously + teicoplanin 200 mg daily intravenously
  32nd day   Tigecycline 50 mg twice a day intravenously three times a week + teicoplanin 200 mg daily intravenously only Saturday + fluconazol 200 mg daily 3 times a week + colomycin 500 000 IU daily intramuscular only Saturday
  35th day   Tigecycline 50 mg twice a day intravenously 3 times a week + teicoplanin 200 mg daily intravenously only Saturday + fluconazol 200 mg daily 3 times a week + colomycin 500 000 IU daily intramuscular Tuesday and Thursday
  37th day   Tigecycline 50 mg B.D intravenously three times a week + teicoplanin 200 mg daily intravenously three times a week after HD + fluconazol 200 mg daily three times a week + colomycin 500 000 IU daily intramuscular Tuesday and Thursday
  40th day   Tigecycline 50 mg twice a day intravenously 3 times a week + teicoplanin 200 mg daily intravenously only Saturday + fluconazol 200 mg daily 3 times a week + colomycin 500 000 IU daily intramuscular 3 times a week after HD
  44th day   Tigecycline 50 mg twice a day intravenously + teicoplanin 200 mg daily intravenously after HD 3 times a week + fluconazol 200 mg daily intravenously 3 times a week + colomycin 1 000 000 IU daily intramuscular 3 times a week
  46th day   Tigecycline 50 mg twice a day intravenously + fluconazol 200 mg daily 3 times a week + colomycin 1 000 000 IU daily intramuscular 3 times a week after HD
  51st day   Amphotericin B 150 mg daily intravenously three times a week + meropenem 500 mg 3 times a day intravenously + colomycin 1 000 000 IU daily intramuscular 3 times a week
  58th day   Amphotericin 150 mg daily intravenously + meropenem 500 mg twice a day intravenously + colomycin 2 000 000 IU daily intramuscular 3 times a week + colomycin 2 500 000 IU daily intramuscular 3 times a week

Abbreviation: HD, hemodialysis.

A CT angiography, performed 6 weeks after recovery, evidenced the "complete thrombosis of the right subclavian vein, internal jugular vein with precaval tract stenosis and thrombosis of the left common femoral vein." Images showed the abdominal presence "of the abscess formation in the left parietocolic facial in the mesosigma tract similar to the involvement of the left fallopian tube, small fluid collection like abscess formation between tail of the pancreas and the gastric lesser curvature." A Tesio catheter was placed in jugular vein after dilatation procedure for jugular stenosis and the left femoral catheter was removed.

For the resistant anemia, it was necessary an hemotransfusion, while was also necessary fresh frozen plasma transfusion for the suspicion of disseminated intravascular coagulation state. The patient was discharged after 3 months in improved clinical conditions, feverless stable hemodynamic state, without respiratory problems and improved inflammatory index, and the resolution of abscess formation between tail of the pancreas and gastric lesser curvature due to antibiotic therapy. The patient went on hemodialysis, 1 month after discharge.

Discussion {#section3-1179547618765761}
==========

Acute pancreatitis is divided in 3 states: (a) mild acute pancreatitis, characterized by absence of organ failure nor local or systemic complication; (b) moderately severe acute pancreatitis, characterized by organ failure that resolves within 48 hours and/or local or systemic complication without persistent organ failure; and (c) severe acute pancreatitis, characterized by persistence of organ failure (\>48 hours). The incidence of pancreatitis is higher in end-stage renal disease state and in PD patients.

Icodextrin produces a chemical irritation in the peritoneum and pancreatic glands and can be the cause of pancreatitis.^[@bibr17-1179547618765761]^ High intra-abdominal pressure caused by peritoneal fluid and nonphysiological composition that are able to promote the premature activation of the proteolytic pancreatic enzyme, local toxicity of peritoneal dialysate,^[@bibr35-1179547618765761],[@bibr36-1179547618765761]^ and high level of uremic toxin and local hypercalcemia are frequent causes of pancreatitis in PD.^[@bibr35-1179547618765761]^

Pancreatic dysfunction can be caused by the elevated gastrointestinal enzymes such as cholecystokinin, glucagon, and gastric inhibitory polypeptide that stimulate the oversecretion of pancreatic enzymes^[@bibr37-1179547618765761]^ and histologic lesion similar to chronic pancreatitis.^[@bibr38-1179547618765761]^

Acute pancreatitis manifests with a sudden sharp severe and persistent epigastric pain; nausea and vomiting that persist for different hours^[@bibr39-1179547618765761]^; fever; tachypnea; hypotension; and retroperitoneal hemorrhage such as Cullen sign and Grey Turner sign.^[@bibr25-1179547618765761]^

Acute pancreatitis can be diagnosed by the sudden onset of epigastric pain with back region radiation, increase in the serum amylase or lipase enzymes 3 times higher than normal range, and evidence of the pancreatitis in the imaging examinations such as CT or MRI.^[@bibr17-1179547618765761]^ In patients on renal replacement therapy, it is necessary to evaluate the clinical and radiological state to diagnose the pancreatitis for the association with high-level amylase and lipase without evidence of pancreatitis^[@bibr40-1179547618765761]^ because of the renal clearance changes. Icodextrin can decrease amylase activity so in PD patients, it is necessary to evaluate the lipase level instead of the amylase level. Pseudocyst formation is one of the complications related to 10% of the pancreatitis, usually 4 weeks after the acute state. Pancreatic tissue necrosis can progress toward liquefaction to develop the pseudocyst that can start in pancreatic duct or can be organized by the parenchymal necrosis that destroys the ducts with high dispersion of the pancreatic secretion. This formation can be associated with abdominal pain, duodenal or vascular obstruction, fistula formation to in adjacent organs, in pleural or pericardium cavity that may cause pleural effusion, or ascites, which can be diagnosed by imaging examination (CT and MRI). About 40% of the pseudocysts improve spontaneously. The other patients should be treated with surgery methods, percutaneous or endoscopic cystogastrostomy drainage ([Table 2](#table2-1179547618765761){ref-type="table"}).

###### 

Evolution of serum amylase and lipase.

![](10.1177_1179547618765761-table2)

  Date                           Amylase, U/L   Lipase, U/L
  ------------------------------ -------------- -------------
  1st day                        137            713
  2nd day (9 [am]{.smallcaps})   194            1189
  2nd day (7 [pm]{.smallcaps})   134            974
  2nd day (9 [pm]{.smallcaps})   120            806
  3rd day                        60             312
  4th day                        12             56
  5th day                        8              40

Few hours before admission, patient did an ambulatory control with normal pancreatic amylase (15 U/L). In the afternoon, the patient went to the hospital for abdominal pain. The sample of the afternoon evidenced amylase 137 U/L and lipase 713 U/L. Reaching a peak of amylase 194 U/L and lipase 1189 U/L, the picture laboratory normalized over 3 days.

Conclusions {#section4-1179547618765761}
===========

In this clinical case, at first, the patient presented 1 episode of acute pancreatitis which demonstrated the increase in the pancreatic enzyme level, resolved within 3 days, whereas the second acute episode occurred in presence of normal amylase and lipase levels. Only the radiologic images (CT scan and MRI) demonstrated the presence of acute complicated pancreatitis with the "numerous communicated pseudo cystic formations." This radiologic finding can be considered an acute idiopathic pancreatitis or a pancreatitis secondary to PD. The patient evidenced complicated candida peritonitis associated with acute pancreatitis and pseudocyst complicated by the overlap of pneumonitis and *A baumannii* sepsis.
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